- Report
- March 2025
- 175 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- February 2025
- 200 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- May 2024
- 134 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- May 2024
- 134 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- May 2024
- 140 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- November 2023
- 262 Pages
Global
From €7109EUR$7,500USD£5,939GBP
- Report
- April 2024
- 30 Pages
Global
From €3365EUR$3,550USD£2,811GBP
- Drug Pipelines
- April 2024
- 50 Pages
Global
From €1422EUR$1,500USD£1,188GBP
- Report
- April 2023
- 147 Pages
Global
From €4691EUR$4,949USD£3,919GBP
- Report
- April 2023
- 147 Pages
Global
From €4691EUR$4,949USD£3,919GBP
- Report
- January 2024
- 200 Pages
Global
From €3933EUR$4,150USD£3,286GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Report
- February 2023
- 385 Pages
Global
From €3384EUR$3,570USD£2,827GBP

Lamivudine is an antiviral medication used to treat immune disorders such as HIV and hepatitis B. It is a nucleoside reverse transcriptase inhibitor (NRTI) that works by blocking the action of the virus’s reverse transcriptase enzyme, which is responsible for the replication of the virus. Lamivudine is used in combination with other drugs to treat HIV and hepatitis B infections. It is also used to prevent mother-to-child transmission of HIV.
Lamivudine is available in both generic and brand-name formulations. It is available in tablet, capsule, and oral solution forms. The drug is available in various strengths and is usually taken once or twice daily.
The market for lamivudine is highly competitive, with many companies offering generic and brand-name formulations. Some of the companies in the market include Mylan, Teva Pharmaceuticals, Cipla, and Sun Pharmaceuticals. Show Less Read more